Anti-CD22 [RFB-4]
Invented at University College London
Anti-CD22, Recombinant [RFB-4]
Invented at University College London
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 152585 |
| Applications | FACS IHC IF |
| Antigen/Gene or Protein Targets | CD22 |
| Reactivity | Human |
| Relevance | Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas. |
| Host | Mouse |
| Immunogen | Tonsil lymphocytes |
| Subclass | IgG1 |
| Formulation | PBS only |
| Concentration | 1mg/ml |
| Molecular Weight (kDa) | 153 |
| Research Area | Adhesion, Cancer, Cell Signaling & Signal Transduction, Immunology, Stem Cell Biology |
| Notes |
Cytoplasmic antigen of mature B lymphocytes. >90% reactivity on peripheral B cells. Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. |
References: 2 entries
Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.
Human B cell development. II. Subpopulations in the human fetus.
Europe PMC ID: 3871452
Add a reference
References: 2 entries
Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.
Human B cell development. II. Subpopulations in the human fetus.
Add a reference
